Found: 13
Select item for more details and to access through your institution.
Diabetes, Obesity and Metabolism.
- Published in:
- Diabetes, Obesity & Metabolism, 2015, v. 17, n. 10, p. i, doi. 10.1111/dom.12373
- Publication type:
- Article
One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2015, v. 17, n. 10, p. 965, doi. 10.1111/dom.12498
- By:
- Publication type:
- Article
Biosimilar insulins: guidance for data interpretation by clinicians and users.
- Published in:
- Diabetes, Obesity & Metabolism, 2015, v. 17, n. 10, p. 911, doi. 10.1111/dom.12491
- By:
- Publication type:
- Article
Weight-sparing effect of insulin detemir: a consequence of central nervous system-mediated reduced energy intake?
- Published in:
- Diabetes, Obesity & Metabolism, 2015, v. 17, n. 10, p. 919, doi. 10.1111/dom.12493
- By:
- Publication type:
- Article
Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial ( EASE-1).
- Published in:
- Diabetes, Obesity & Metabolism, 2015, v. 17, n. 10, p. 928, doi. 10.1111/dom.12494
- By:
- Publication type:
- Article
GSK2374697, a long duration glucagon-like peptide-1 ( GLP-1) receptor agonist, reduces postprandial circulating endogenous total GLP-1 and peptide YY in healthy subjects.
- Published in:
- Diabetes, Obesity & Metabolism, 2015, v. 17, n. 10, p. 1007, doi. 10.1111/dom.12533
- By:
- Publication type:
- Article
Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study.
- Published in:
- Diabetes, Obesity & Metabolism, 2015, v. 17, n. 10, p. 974, doi. 10.1111/dom.12534
- By:
- Publication type:
- Article
A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus.
- Published in:
- Diabetes, Obesity & Metabolism, 2015, v. 17, n. 10, p. 984, doi. 10.1111/dom.12538
- By:
- Publication type:
- Article
Rosiglitazone treatment and cardiovascular disease in the Veterans Affairs Diabetes Trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2015, v. 17, n. 10, p. 949, doi. 10.1111/dom.12487
- By:
- Publication type:
- Article
Progression to insulin therapy among patients with type 2 diabetes treated with sitagliptin or sulphonylurea plus metformin dual therapy.
- Published in:
- Diabetes, Obesity & Metabolism, 2015, v. 17, n. 10, p. 956, doi. 10.1111/dom.12489
- By:
- Publication type:
- Article
Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2015, v. 17, n. 10, p. 936, doi. 10.1111/dom.12503
- By:
- Publication type:
- Article
Islet amyloid inhibitors improve glucose homeostasis in a transgenic mouse model of type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2015, v. 17, n. 10, p. 1003, doi. 10.1111/dom.12529
- By:
- Publication type:
- Article
Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study.
- Published in:
- Diabetes, Obesity & Metabolism, 2015, v. 17, n. 10, p. 994, doi. 10.1111/dom.12540
- By:
- Publication type:
- Article